Intercell is an innovative biotechnology company focused on the design and development of novel vaccines for the prevention and treatment of infectious diseases. Our products target markets with substantial unmet medical needs.

A listed stock corporation since 2005

Intercell is listed on the Vienna stock exchange (VSE) under the symbol “ICLL” since February 2005.

Keep updated with latest data on Intercell shares.

Intercell has a total of 48,592,219 issued shares of common stock, which includes 315,889 shares of treasury stock. See percentage of our major shareholders.

See a list of the institutes and analysts who regularly deal with economic analysis of Intercell.

Ordinary Shareholders' Meetings are held once a year. All documents related to the last meeting are published here.

In our financial calendar you will find upcoming events ranging from the Annual General Meeting as well as investor information and dates for forthcoming reports and analysis.

Visit our download area to view and download our Annual Reports, Quarterly Reports and presentations.

Our corporate team is committed to good Corporate Governance Practice in agreement with the Austrian Code of Corporate Governance.

Our list of frequent asked questions gives you the basic information about the economic foundations of Intercell.

Do not hesitate to contact us for additional information.